CLINICAL TRIALS PROFILE FOR BIKTARVY

All Clinical Trials for Biktarvy

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03259698 ↗	Optimizing the Delivery of HIV nPEP	Recruiting	Canadian Institutes of Health Research (CIHR)	Phase 2	2021-10-01	Despite decades of traditional prevention efforts based on behavior change and condom use, Ontario has seen over 700 new HIV infections annually over the past 10 years. Post-exposure prophylaxis (PEP) is one such approach, in which uninfected persons use 28 days of antiretroviral medications (ARVs) shortly after an HIV exposure to minimize the risk of acquiring HIV. PEP is highly efficacious, is considered a standard of care intervention based on medical and ethical grounds, and is supported by treatment guidelines. Yet several implementation challenges have limited its clinical and public health impact in Ontario, where no formal PEP policy exists. Our proposal seeks to optimize two aspects of delivering PEP for sexual exposures (nPEP). Results will inform the development of a standardized approach to nPEP both province-wide and elsewhere. Thus study has pragmatic, multicenter randomized controlled trial using a 2x2 factorial design to determine whether the proportion of nPEP patients that successfully complete follow-up: 1. is higher among those receiving mobile phone-based text messaging support than among those receiving standard care; and 2. is non-inferior among those receiving care from a sexual health clinic nurse compared to those receiving hospital-based physician care. The prospective, randomized, non-blinded, 2x2 factorial trial that will enroll 318 study participants in Toronto. In Intervention A, we will randomize half of study participants to a text messaging support service ('WelTel'), in which a trained, community-based counselor provides standardized weekly 'check-in' messages during their 12-week course of PEP follow-up. The other half will receive standard care, which does not include any form of active outreach or reminders outside of scheduled appointments. In Intervention B, we will randomize half of participants to receive nurse-led care for PEP follow-up at a local sexual health clinic; the other half will receive standard care by a hospital-based ID physician. The specific activities for each follow-up visit will be clearly defined in a medical directive. In keeping with Ontario legislation on medical directives, nurses will review cases with their authorizing physician or nurse practitioner on a routine basis.
NCT03259698 ↗	Optimizing the Delivery of HIV nPEP	Recruiting	CIHR Canadian HIV Trials Network	Phase 2	2021-10-01	Despite decades of traditional prevention efforts based on behavior change and condom use, Ontario has seen over 700 new HIV infections annually over the past 10 years. Post-exposure prophylaxis (PEP) is one such approach, in which uninfected persons use 28 days of antiretroviral medications (ARVs) shortly after an HIV exposure to minimize the risk of acquiring HIV. PEP is highly efficacious, is considered a standard of care intervention based on medical and ethical grounds, and is supported by treatment guidelines. Yet several implementation challenges have limited its clinical and public health impact in Ontario, where no formal PEP policy exists. Our proposal seeks to optimize two aspects of delivering PEP for sexual exposures (nPEP). Results will inform the development of a standardized approach to nPEP both province-wide and elsewhere. Thus study has pragmatic, multicenter randomized controlled trial using a 2x2 factorial design to determine whether the proportion of nPEP patients that successfully complete follow-up: 1. is higher among those receiving mobile phone-based text messaging support than among those receiving standard care; and 2. is non-inferior among those receiving care from a sexual health clinic nurse compared to those receiving hospital-based physician care. The prospective, randomized, non-blinded, 2x2 factorial trial that will enroll 318 study participants in Toronto. In Intervention A, we will randomize half of study participants to a text messaging support service ('WelTel'), in which a trained, community-based counselor provides standardized weekly 'check-in' messages during their 12-week course of PEP follow-up. The other half will receive standard care, which does not include any form of active outreach or reminders outside of scheduled appointments. In Intervention B, we will randomize half of participants to receive nurse-led care for PEP follow-up at a local sexual health clinic; the other half will receive standard care by a hospital-based ID physician. The specific activities for each follow-up visit will be clearly defined in a medical directive. In keeping with Ontario legislation on medical directives, nurses will review cases with their authorizing physician or nurse practitioner on a routine basis.
NCT03259698 ↗	Optimizing the Delivery of HIV nPEP	Recruiting	St. Michael's Hospital, Toronto	Phase 2	2021-10-01	Despite decades of traditional prevention efforts based on behavior change and condom use, Ontario has seen over 700 new HIV infections annually over the past 10 years. Post-exposure prophylaxis (PEP) is one such approach, in which uninfected persons use 28 days of antiretroviral medications (ARVs) shortly after an HIV exposure to minimize the risk of acquiring HIV. PEP is highly efficacious, is considered a standard of care intervention based on medical and ethical grounds, and is supported by treatment guidelines. Yet several implementation challenges have limited its clinical and public health impact in Ontario, where no formal PEP policy exists. Our proposal seeks to optimize two aspects of delivering PEP for sexual exposures (nPEP). Results will inform the development of a standardized approach to nPEP both province-wide and elsewhere. Thus study has pragmatic, multicenter randomized controlled trial using a 2x2 factorial design to determine whether the proportion of nPEP patients that successfully complete follow-up: 1. is higher among those receiving mobile phone-based text messaging support than among those receiving standard care; and 2. is non-inferior among those receiving care from a sexual health clinic nurse compared to those receiving hospital-based physician care. The prospective, randomized, non-blinded, 2x2 factorial trial that will enroll 318 study participants in Toronto. In Intervention A, we will randomize half of study participants to a text messaging support service ('WelTel'), in which a trained, community-based counselor provides standardized weekly 'check-in' messages during their 12-week course of PEP follow-up. The other half will receive standard care, which does not include any form of active outreach or reminders outside of scheduled appointments. In Intervention B, we will randomize half of participants to receive nurse-led care for PEP follow-up at a local sexual health clinic; the other half will receive standard care by a hospital-based ID physician. The specific activities for each follow-up visit will be clearly defined in a medical directive. In keeping with Ontario legislation on medical directives, nurses will review cases with their authorizing physician or nurse practitioner on a routine basis.
NCT03259698 ↗	Optimizing the Delivery of HIV nPEP	Recruiting	Unity Health Toronto	Phase 2	2021-10-01	Despite decades of traditional prevention efforts based on behavior change and condom use, Ontario has seen over 700 new HIV infections annually over the past 10 years. Post-exposure prophylaxis (PEP) is one such approach, in which uninfected persons use 28 days of antiretroviral medications (ARVs) shortly after an HIV exposure to minimize the risk of acquiring HIV. PEP is highly efficacious, is considered a standard of care intervention based on medical and ethical grounds, and is supported by treatment guidelines. Yet several implementation challenges have limited its clinical and public health impact in Ontario, where no formal PEP policy exists. Our proposal seeks to optimize two aspects of delivering PEP for sexual exposures (nPEP). Results will inform the development of a standardized approach to nPEP both province-wide and elsewhere. Thus study has pragmatic, multicenter randomized controlled trial using a 2x2 factorial design to determine whether the proportion of nPEP patients that successfully complete follow-up: 1. is higher among those receiving mobile phone-based text messaging support than among those receiving standard care; and 2. is non-inferior among those receiving care from a sexual health clinic nurse compared to those receiving hospital-based physician care. The prospective, randomized, non-blinded, 2x2 factorial trial that will enroll 318 study participants in Toronto. In Intervention A, we will randomize half of study participants to a text messaging support service ('WelTel'), in which a trained, community-based counselor provides standardized weekly 'check-in' messages during their 12-week course of PEP follow-up. The other half will receive standard care, which does not include any form of active outreach or reminders outside of scheduled appointments. In Intervention B, we will randomize half of participants to receive nurse-led care for PEP follow-up at a local sexual health clinic; the other half will receive standard care by a hospital-based ID physician. The specific activities for each follow-up visit will be clearly defined in a medical directive. In keeping with Ontario legislation on medical directives, nurses will review cases with their authorizing physician or nurse practitioner on a routine basis.
NCT03499483 ↗	Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)	Recruiting	Fenway Community Health	Phase 4	2019-01-24	Study will evaluate the safety and tolerability of once daily Biktarvy for 28 days for prevention of HIV infection in HIV-1-seronegative adults after high-risk sexual contact. (non-occupational post exposure prophylaxis - nPEP)
NCT03502005 ↗	Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1	Completed	Gilead Sciences	Phase 4	2018-03-01	This study evaluates the efficacy, safety and tolerability of switching from the older, established single tablet regimen of ATRIPLA® (EFV/FTC/TDF) to a new single tablet regimen of BIKTARVY® (BIC/FTC/TAF), in HIV-1 infected adult subjects who are virologically suppressed (HIV-1 RNA
NCT03502005 ↗	Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1	Completed	Midland Research Group, Inc.	Phase 4	2018-03-01	This study evaluates the efficacy, safety and tolerability of switching from the older, established single tablet regimen of ATRIPLA® (EFV/FTC/TDF) to a new single tablet regimen of BIKTARVY® (BIC/FTC/TAF), in HIV-1 infected adult subjects who are virologically suppressed (HIV-1 RNA

Clinical Trial Conditions for Biktarvy

Condition Name

Condition Name for Biktarvy
Intervention	Trials
HIV-1-infection	13
HIV Infections	7
Human Immunodeficiency Virus	5
Hiv	5

Condition MeSH

Condition MeSH for Biktarvy
Intervention	Trials
HIV Infections	18
Acquired Immunodeficiency Syndrome	10
Infections	5
Communicable Diseases	4

Clinical Trial Locations for Biktarvy

Trials by Country

Trials by Country for Biktarvy
Location	Trials
United States	101
Canada	10
Italy	7
United Kingdom	6
Germany	6

Trials by US State

Trials by US State for Biktarvy
Location	Trials
California	7
Georgia	7
Florida	6
Massachusetts	6
Texas	6

Clinical Trial Progress for Biktarvy

Clinical Trial Phase

Clinical Trial Phase for Biktarvy
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	2

Clinical Trial Status

Clinical Trial Status for Biktarvy
Clinical Trial Phase	Trials
Recruiting	17
Not yet recruiting	9
Active, not recruiting	4

Clinical Trial Sponsors for Biktarvy

Sponsor Name

Sponsor Name for Biktarvy
Sponsor	Trials
Gilead Sciences	18
ViiV Healthcare	4
Brigham and Women's Hospital	3

Sponsor Type

Sponsor Type for Biktarvy
Sponsor	Trials
Other	61
Industry	28
UNKNOWN	1

BIKTARVY clinical trials update, market analysis, and exclusivity-driven projection (US and key ex-US markets)

Last updated: May 21, 2026

Executive summary: Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide; BIC/FTC/TAF) remains the leading branded, single-tablet regimen in HIV combination therapy in the US and is still expanding share in treatment-naïve and virologically suppressed switching cohorts. Short-term growth is supported by broad guideline positioning and high persistence driven by tolerability and once-daily dosing. Medium-term unit growth is constrained by (1) persistent competitive pressure from dolutegravir-based generics and long-acting options entering the market, and (2) pricing and payer controls. From a patent-and-regulatory angle, any generic entry risk is largely governed by the US Orange Book patent list for Biktarvy and the timing of patent expirations, plus the availability of authorized generics or settlement outcomes from Paragraph IV challenges. Ex-US, local formularies and tender systems determine revenue resilience more than global patent structure.

What is the latest clinical trials update for Biktarvy (bictegravir/FTC/TAF)?

Answer: Recent clinical activity for Biktarvy centers on durability in treatment-naïve and switch populations, real-world evidence on persistence and resistance, and expanded data supporting use in broader baseline resistance and comorbidity settings. In parallel, HIV competitors have moved aggressively in long-acting formulations, raising the bar for “switch” justification and driving more head-to-head and cohort analyses rather than brand-new mechanism studies for Biktarvy.

Which trial cohorts matter for market share (naïve, switch, and resistance)?

Key commercial relevance is attached to data that de-risk initiation and switching:

• Treatment-naïve efficacy and resistance outcomes: Proportion achieving and maintaining HIV-1 RNA suppression at Week 48 and beyond, with resistance-selected failures monitored through genotype/phenotype.
• Virologically suppressed switching: Sustained suppression after switching from INSTI- or PI-based regimens without treatment failure.
• Baseline resistance and adherence risk: Outcomes in patients with prior NNRTI or NRTI exposure, and in settings where adherence is variable.
• Comorbidity and renal/bone safety: Data that preserves clinician confidence in long-term TAF-based therapy.
• Special populations: Data in hepatic impairment, coinfections, and pregnancy planning where regimen selection is sensitive to safety signals.

How do ongoing and recently reported studies affect payer and guideline uptake?

For branded HIV regimens, payer uptake is driven by:

• documented durability (low failure rates),
• low discontinuation,
• low virologic rebound,
• and safety profiles that reduce downstream costs (renal monitoring, bone health interventions, regimen modifications).

Clinical trial updates that strengthen these endpoints typically translate into higher formulary placement and more switching.

What endpoints are most likely to move the commercial needle?

From a projection standpoint, the strongest demand signals are:

• Discontinuation rates (especially for tolerability),
• Time to virologic rebound in “switch” cohorts,
• Resistance emergence after failure,
• and pharmacokinetic/food effect data that reduce prescribing friction.

How big is the Biktarvy market today and what drives demand?

Answer: Demand is sustained by a large patient base on effective INSTI-based regimens and ongoing switching from older single-tablet regimens. Growth is driven less by new initiation alone and more by switch activity, persistence, and guideline-adjacent prescribing.

Market structure that shapes Biktarvy revenue

• High retention on INSTI regimens: Once suppressed, many patients remain on a regimen absent tolerability or resistance issues.
• Switch-to-better-safety logic: BIC/FTC/TAF is used as a switch option from regimens with less favorable renal/bone profiles.
• US payer controls: Rebates, preferred status, and step therapy affect net price realization even where gross prescriptions rise.
• Competition from dolutegravir/TAF fixed-dose generics: As INSTI generics expand, Biktarvy’s “value case” shifts toward safety and tolerability, not efficacy alone.

Segment demand: treatment-naïve vs switch

Commercially, Biktarvy typically benefits from both:

• first-line initiation where clinicians choose a high barrier-to-resistance INSTI regimen, and
• switching from older branded or generic NRTI backbones, particularly where TAF advantages are emphasized.

Switch cohorts are typically where persistence stays high and where brand momentum can outrun initiation growth.

How do long-acting HIV drugs change the demand outlook?

Long-acting agents shift the switching equation. Even if Biktarvy maintains strong oral-daily retention, long-acting therapies:

• increase patient and clinician attention to alternative dosing,
• introduce “switch constraints” (clinic infrastructure, eligibility criteria),
• and can pull some share from oral regimens in adherent populations.

That said, oral daily INSTI regimens generally continue to dominate overall volume for most payers due to cost and operational simplicity.

When does Biktarvy lose exclusivity and what is the patent expiration timeline?

Answer: Biktarvy’s generic entry risk is tied to US patent expirations and any regulatory exclusivities (including new chemical entity protections, if applicable for specific patent families). The operational question for projection is not “when the last patent expires” but when the Orange Book-listed patents that cover the product (and any formulation or method-of-use claims) expire or are invalidated, allowing full label generic substitution.

US Orange Book framework driving generic launch risk

Biktarvy’s US exclusivity and generic barrier typically arise from:

• composition-of-matter patents covering bictegravir,
• combination patents covering the fixed-dose combination,
• formulation and process patents tied to TAF/FTC component integration,
• and potentially method-of-use patents relevant to INSTI-based regimens.

Paragraph IV filings, if present, would map to which patents are challenged and thus define feasible launch dates.

How to translate patent expiry into a projection window

For business planning, generic entry is forecast in a two-stage pattern:

1. Launch window after first exploitable patent expiry (partial barriers removed, label changes possible)
2. Peak erosion window after additional barriers fall or litigation settles (more generics enter, broader substitution)

Market impact is usually steepest after multiple barriers are cleared.

What patents protect Biktarvy in the US, and how many are on the Orange Book?

Answer: Biktarvy’s US protection is represented by multiple Orange Book listed patents spanning composition, formulation, and possibly method-of-use categories. The count and specific expiration dates determine both:

• likelihood of generic timing success,
• and how quickly the market price erodes once entry begins.

Which patent types matter for generic viability?

• Composition-of-matter: hardest to design around; drives the longest exclusivity.
• Combination claims: may block generics that attempt a “near design-around” fixed-dose combination.
• Formulation/process claims: can block generics even if composition is not directly contested, depending on claim coverage and design-around feasibility.
• Method-of-use claims: more relevant if generics seek to launch with narrower labeling or if challenges are to use-related claims.

Are there Paragraph IV challenges or biosimilar-style risks for Biktarvy?

Answer: For a small-molecule HIV regimen like Biktarvy, the relevant pathway is ANDA Paragraph IV (not biosimilars). Any Paragraph IV challenge would target Orange Book patents and create a litigation timeline that can shift generic entry dates materially.

What does the typical litigation timeline imply for revenue?

If Paragraph IV challenges are filed, US law creates a structured process:

• automatic 30-month stay (if applicable) tied to the date of notice,
• litigation outcomes (settlement, consent judgment, or final court decision),
• and label and launch sequencing.

For revenue projection, the key is not filing date alone but:

• whether the stay is triggered,
• which patents are actually litigated,
• and the settlement’s effective launch date.

What formulations are protected for BIKTARVY and what generic entry risks exist?

Answer: For fixed-dose tablets, the generic entry risk typically concentrates on the combination product and its formulation and manufacturing claims. A generic that makes a different formulation, different process, or different dosage strength must still avoid infringing valid claims tied to the approved product.

How formulation claims affect design-around strategies

If formulation/process patents are enforced:

• generics may have to alter manufacturing steps,
• change excipient strategy,
• or pursue alternative process routes that must avoid infringement. These steps increase cost, time, and litigation risk.

What “labeling barriers” slow generic substitution?

Even if a generic can launch on a label that carves around method-of-use claims, substitution can lag due to:

• prescriber comfort and brand loyalty,
• payer contracting and formulary positioning,
• and patient-specific regimen continuity.

What is the FDA regulatory status of Biktarvy (approvals, labeling, and extensions)?

Answer: Biktarvy is an FDA-approved antiretroviral fixed-dose combination tablet regimen with labeling that supports multiple adult and adolescent indications depending on age, treatment history, and baseline characteristics as updated over time.

How FDA labeling expands commercial addressability

Each labeling expansion can add volume via:

• enabling treatment-naïve use in more patient subsets,
• enabling switching from more prior regimens,
• or broadening use for patients with comorbidities.

Label breadth also drives formulary inclusion.

How does Biktarvy compare with competitors (Genvoya, Dovato, Cabenuva, Symtuza, Triumeq, and dolutegravir/TAF generics)?

Answer: Biktarvy’s core competitive advantage is simplicity (single-tablet, once-daily), high durability, and a strong safety and tolerability profile associated with TAF-based therapy plus bictegravir’s high barrier. Competitive pressure comes from:

• lower-cost INSTI regimens and NRTI backbones as generics penetrate,
• and long-acting CAB/RPV for patients eligible for injection therapy.

Comparative demand drivers

• Switch attractiveness: Biktarvy often scores well on clinician confidence for tolerability and renal/bone considerations.
• Payer price sensitivity: generic penetration pressures net revenue.
• Long-acting eligibility: can redirect some switch volume to injection programs if total cost is acceptable.

What market projection should be used for Biktarvy through the next patent and payer cycles?

Answer: Near term (next 12 to 24 months): modest growth or stable-to-mid growth in prescription volume driven by persistence and guideline alignment, with net revenue influenced by pricing strategy and payer negotiations. Medium term (24 to 60 months): growth shifts from initiation to retention and share maintenance, with incremental erosion probability rising as US patent barriers loosen and generic pricing pressure intensifies. Long term (post-exclusivity window): revenue declines accelerate as multiple generics enter and payer substitution becomes routine unless additional regulatory or patent settlements delay entry.

Business-grade projection structure (what to model)

For Biktarvy, the model should split revenue into:

1. Base volume growth (patient growth, guideline adherence, persistence)
2. Share drift vs oral INSTI competitors and long-acting alternatives
3. Net price (rebates, preferred contracting, outcomes-based contracting)
4. Generic entry shock tied to patent and settlement timelines

What determines “how fast” erosion happens after entry

• number of ANDA entrants and whether there are authorized generics,
• strength of litigation outcomes delaying entry,
• payer policy speed for switching,
• and whether clinicians continue brand use due to tolerability and resistance profiles.

Which companies are positioned to challenge Biktarvy and what is the competitive landscape?

Answer: The competitive landscape for an orally dosed fixed-dose HIV regimen is shaped by generic manufacturers with ANDA capability and litigation experience, plus branded competitors with stronger value propositions in specific patient segments (e.g., long-acting eligibility).

How to interpret competitive moves

• Generic entrants signal expectations that at least part of the Orange Book barrier is exploitable.
• Branded competitors with differentiated safety or dosing target the switch segment first because it has lower churn barriers.

What licensing and settlement scenarios could change generic timing?

Answer: Settlements in HIV patent litigation typically aim to trade off:

• immediate launch vs delayed entry,
• court risk vs market share preservation,
• and sometimes carve-outs tied to label scope.

What to look for in settlement terms

• effective launch date(s),
• scope of ANDA approval (label carve-outs),
• and non-infringement or covenants shaping future patent attacks.

Key Takeaways

• Biktarvy’s demand is supported by high durability, switch penetration, and strong clinician/payer confidence in an oral once-daily, single-tablet INSTI regimen.
• Growth is increasingly driven by persistence and switching rather than purely new initiation.
• Competitive pressure will concentrate on net price erosion from oral INSTI generics and partial share reallocation to long-acting injection options.
• Generic entry timing depends on Orange Book patent expiration and litigation outcomes, with market impact steepening after multiple barriers clear.
• Projections should model a staged erosion curve tied to patent and settlement timelines, not a single “last patent” date.

FAQs

1. How should I forecast Biktarvy net revenue considering payer rebates and preferred formulary placement?
2. What are the most important US Orange Book patents that drive ANDA launch timing for Biktarvy?
3. How do switch studies and discontinuation endpoints correlate with real-world persistence for Biktarvy?
4. What is the impact of long-acting cabotegravir/rilpivirine on switching patterns away from Biktarvy?
5. What design-around options do generic developers typically pursue for fixed-dose INSTI/NRTI combinations like Biktarvy?

References (APA)

No sources provided in the prompt.